05 February 2014

Targeting Tyrosine Kinase Pathway: Where do we stand?

All credit to Majdy Idrees, FPVRI, Head of SAPH, Riyadh Military Hospital, Vancouver | Canada

Presented at 7th Annual Joint Pulmonary Hypertension Assembly, SAPH2014, May 1-3 2014, Muscat, Oman

 

Additional key-words:  imatinib,tyrosine kinase inhibitor,vasoreactivity,IMPRES,cancer

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg